Biblio Discovery — Demo Discovery Service

8 hasil untuk "Kumar, Varun M"

Menampilkan 1–8 · 0,38 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Explaining variation in the uptake of HPV vaccination in England

    Whynes David K; Kumar Varun M

    BMC Public Health, Vol. 11 No. 1 · 2011 · Inggris · DOAJ Scopus

    Abstract Background In England, two national programmes of HPV vaccination for girls have been instituted, a routine programme for 12- and 13-year-olds and a catch-up programme for 17- and 18-year-olds. Uptake rates across the country have been far from uniform, and this research sought to identify…

    Juga tersedia di: PubMed Central

  2. Artikel Jurnal Teks lengkap

    Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

    Thokala, Praveen; Stevenson, Matt; Kumar, Varun M. dkk.

    Cost Eff Resour Alloc · 2020 · Inggris · PubMed Central

    BACKGROUND: Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of treatment. Nusinersen is a disease-modifying therapy for patients with SMA…

  3. Artikel Jurnal Teks lengkap

    Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis

    Whittington, Melanie D.; McQueen, R. Brett; Ollendorf, Daniel A. dkk.

    J Manag Care Spec Pharm · 2019 · Inggris · PubMed Central

    This article has been corrected. Please see J Manag Care Spec Pharm. 2019 Jun;25(6):726. BACKGROUND: Rheumatoid arthritis is associated with a societal burden greater than $39 billion annually. Novel treatments, known as targeted immune modulators (TIMs), are expensive but effective, producing…

  4. Artikel Jurnal Teks lengkap

    Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

    Whittington, Melanie D.; McQueen, R. Brett; Ollendorf, Daniel A. dkk.

    JAMA Pediatr · 2018 · Inggris · PubMed Central

    IMPORTANCE: Among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the rate of 5-year disease-free survival is 10% to 20%. Approval of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option…

  5. Artikel Jurnal Teks lengkap

    Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

    Whittington, Melanie D.; McQueen, R. Brett; Ollendorf, Daniel A. dkk.

    JAMA Netw Open · 2019 · Inggris · PubMed Central

    IMPORTANCE: Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option for B-cell lymphoma. It is expected to have long-term survival benefits; however, long-term survival data are limited. OBJECTIVE: To estimate the long-term…